Insilico Medicine said in a Hong Kong Stock Exchange announcement, reported by 36Kr, that it presented preliminary positive data from the first-in-human Phase I trial of ISM6331 in a rapid oral presentation at the 2026 ESMO Congress. ISM6331 is an investigational oral pan-TEAD inhibitor designed with the aid of the company’s Chemistry42 generative AI platform. With an August 14, 2026 data cutoff, the company reported a 40% objective response rate among evaluable mesothelioma participants receiving 130 mg once daily and a 68.2% disease control rate across the 30–130 mg range at the first tumor assessment.